

Yugang Dong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3866773/publications.pdf>

Version: 2024-02-01

80
papers

880
citations

566801

15
h-index

642321

23
g-index

85
all docs

85
docs citations

85
times ranked

1305
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Significance of Mean and Pulse Pressure in Patients With Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2022, 79, 241-250.	1.3	14
2	Ischemic risk in patients with heart failure with preserved ejection fraction: A post hoc analysis of the TOPCAT data. <i>Atherosclerosis</i> , 2022, 344, 1-6.	0.4	3
3	Role of N6-methyladenosine Modification in Cardiac Remodeling. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 774627.	1.1	5
4	Loss of m6A Methyltransferase METTL5 Promotes Cardiac Hypertrophy Through Epitranscriptomic Control of SUZ12 Expression. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 852775.	1.1	10
5	Associations of BMI with mortality in HFpEF patients with concomitant diabetes with insulin versus non-insulin treatment. <i>Diabetes Research and Clinical Practice</i> , 2022, 185, 109805.	1.1	2
6	Cardiac ISL1-Interacting Protein, a Cardioprotective Factor, Inhibits the Transition From Cardiac Hypertrophy to Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 857049.	1.1	0
7	Thyroid hormones inhibit apoptosis of macrophage induced by oxidized low-density lipoprotein. <i>BioFactors</i> , 2022, 48, 86-99.	2.6	3
8	Transplantation of a beating heart: A first in man. <i>The Lancet Regional Health - Western Pacific</i> , 2022, 23, 100449.	1.3	2
9	Signaling cascades in the failing heart and emerging therapeutic strategies. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 134.	7.1	18
10	Efficacy of Intensive Treatment vs. Standard Treatment of Compound Danshen Dripping Pills in Refractory Angina Patients With Incomplete Revascularization (INCODER Study): Study Protocol for a Multicenter, Double-Blind, Randomized Controlled, Superiority Trial. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 860059.	1.1	0
11	Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment. <i>ESC Heart Failure</i> , 2022, 9, 2567-2575.	1.4	10
12	First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1 ⁺ non-small cell lung cancer (NSCLC) or mesothelioma. <i>Journal of Clinical Oncology</i> , 2022, 40, 9071-9071.	0.8	5
13	Automatic annotation of local activation time was improved in idiopathic right ventricular outflow tract ventricular arrhythmia by novel electrogram "Lumipoint" algorithm. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 61, 79-85.	0.6	1
14	Association of physical activity and risk of atrial fibrillation in heart failure with preserved ejection fraction. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 247-253.	1.1	5
15	Cardiac hemodynamic response to the 6-minute walk test in patients with intestinal carcinoma undergoing bevacizumab treatment. <i>Annals of Palliative Medicine</i> , 2021, 10, 1362-1369.	0.5	1
16	Effectiveness of Levoamlodipine Maleate for Hypertension Compared with Amlodipine Besylate: a Pragmatic Comparative Effectiveness Study. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 41-50.	1.3	3
17	Meta-analysis of metabolic syndrome and its individual components with risk of atrial fibrillation in different populations. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 90.	0.7	19
18	Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4-5 Chronic Kidney Disease or on Dialysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 273-281.	1.3	19

#	ARTICLE	IF	CITATIONS
19	C2HEST score predicts clinical outcomes in heart failure with preserved ejection fraction: a secondary analysis of the TOPCAT trial. <i>BMC Medicine</i> , 2021, 19, 44.	2.3	11
20	Comparative Effectiveness and Safety of Non- ν Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. <i>Stroke</i> , 2021, 52, 1225-1233.	1.0	26
21	Meta-analysis of type 1 diabetes mellitus and risk of cardiovascular disease. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107833.	1.2	16
22	Visit-to-Visit Blood Pressure Variability and Clinical Outcomes in Patients With Heart Failure With Preserved Ejection Fraction. <i>Hypertension</i> , 2021, 77, 1549-1558.	1.3	16
23	Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 618816.	1.1	13
24	Effect of aggressive diuresis in acute heart failure with reduced and preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 3248-3256.	1.4	8
25	Association of Body-Weight Fluctuation With Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 689591.	1.1	5
26	An electrographic AV optimization for the maximum integrative atrioventricular and ventricular resynchronization in CRT. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 288.	0.7	0
27	Weight Change and Mortality Risk in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 681726.	1.1	7
28	Circle the Cardiac Remodeling With circRNAs. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 702586.	1.1	7
29	The cardiac translational landscape reveals that micropeptides are new players involved in cardiomyocyte hypertrophy. <i>Molecular Therapy</i> , 2021, 29, 2253-2267.	3.7	24
30	Cardiac CIP protein regulates dystrophic cardiomyopathy. <i>Molecular Therapy</i> , 2021, , .	3.7	7
31	Electrophysiological characteristics of epicardial to endocardial breakthrough in intractable cavotricuspid isthmus-dependent atrial flutter. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 462-471.	0.5	2
32	Association of long-term SBP with clinical outcomes and quality of life in heart failure with preserved ejection fraction: an analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. <i>Journal of Hypertension</i> , 2021, 39, 1378-1385.	0.3	4
33	Major depression and clinical outcomes in patients with heart failure with preserved ejection fraction. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13401.	1.7	6
34	Case Report: Area of Focus of Myocardial Infarction With Non-obstructive Coronary Arteries in Eosinophilic Granulomatosis With Polyangiitis. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 731897.	1.1	1
35	Prognostic Value of Cysteine-Rich Protein 61 Combined with N-Terminal Pro-B-Type Natriuretic Peptide for Mortality in Acute Heart Failure Patients with and without Chronic Kidney Disease. <i>CardioRenal Medicine</i> , 2020, 10, 11-21.	0.7	3
36	Transcribed Ultraconserved Regions, Uc.323, Ameliorates Cardiac Hypertrophy by Regulating the Transcription of CPT1b (Carnitine Palmitoyl transferase 1b). <i>Hypertension</i> , 2020, 75, 79-90.	1.3	20

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of xuezhikang once per day versus two times per day in patients with mild to moderate hypercholesterolaemia (APEX study): a protocol for a multicentre, prospective randomised controlled, open-label, non-inferiority study. <i>BMJ Open</i> , 2020, 10, e034585.	0.8	3
38	Sex-Specific Associations of Risks and Cardiac Structure and Function With Microalbumin/Creatinine Ratio in Diastolic Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 579400.	1.1	2
39	Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT. <i>ESC Heart Failure</i> , 2020, 7, 3801-3809.	1.4	2
40	Adaptation of endothelial cells to shear stress under atheroprone conditions by modulating internalization of vascular endothelial cadherin and vinculin. <i>Annals of Translational Medicine</i> , 2020, 8, 1423-1423.	0.7	10
41	Hispidulin Attenuates Cardiac Hypertrophy by Improving Mitochondrial Dysfunction. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 582890.	1.1	7
42	Association of hyponatraemia and renal function in type 1 cardiorenal syndrome. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13269.	1.7	4
43	Association between retinal arterial narrowing and left ventricular diastolic dysfunction in masked hypertensives. <i>Journal of Clinical Hypertension</i> , 2020, 22, 1050-1058.	1.0	2
44	CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 763-772.	1.3	8
45	Angiotensin-Like Protein 7 and Short-Term Mortality in Acute Heart Failure. <i>CardioRenal Medicine</i> , 2020, 10, 116-124.	0.7	6
46	Role of Exosomal miRNAs in Heart Failure. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 592412.	1.1	26
47	Nocturnal systolic hypertension is a risk factor for cardiac damage in the untreated masked hypertensive patients. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1666-1674.	1.0	5
48	Maf1 ameliorates cardiac hypertrophy by inhibiting RNA polymerase III through ERK1/2. <i>Theranostics</i> , 2019, 9, 7268-7281.	4.6	27
49	Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy. <i>Lipids in Health and Disease</i> , 2019, 18, 32.	1.2	7
50	Electrophysiological characteristics of the earliest activation site in idiopathic right ventricular outflow tract arrhythmias under mini-€electrode mapping. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 642-650.	0.8	6
51	Diastolic Reverse Dipping Pattern Is the Predictor for the Echocardiographic Changes in the Untreated Masked Hypertensive Patients. <i>American Journal of Hypertension</i> , 2019, 32, 588-596.	1.0	6
52	Association of household secondhand smoke exposure and mortality risk in patients with heart failure. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 280.	0.7	6
53	The association of metabolic syndrome components and chronic kidney disease in patients with hypertension. <i>Lipids in Health and Disease</i> , 2019, 18, 229.	1.2	35
54	Lycopene protects against pressure overload-induced cardiac hypertrophy by attenuating oxidative stress. <i>Journal of Nutritional Biochemistry</i> , 2019, 66, 70-78.	1.9	34

#	ARTICLE	IF	CITATIONS
55	The role of angiotensin-like protein 4 in phenylephrine-induced cardiomyocyte hypertrophy. <i>Bioscience Reports</i> , 2019, 39, .	1.1	7
56	Association of Cyr61-cysteine-rich protein 61 and short-term mortality in patients with acute heart failure and coronary heart disease. <i>Biomarkers in Medicine</i> , 2019, 13, 1589-1597.	0.6	5
57	Evaluation of the therapeutic effects of QuickOpt optimization in Chinese patients with chronic heart failure treated by cardiac resynchronization. <i>Scientific Reports</i> , 2018, 8, 4259.	1.6	8
58	Overweight Without Central Obesity, Cardiovascular Risk, and All-Cause Mortality. <i>Mayo Clinic Proceedings</i> , 2018, 93, 709-720.	1.4	14
59	Risk of Cardiovascular Mortality Associated With Serum Sodium and Chloride in the General Population. <i>Canadian Journal of Cardiology</i> , 2018, 34, 999-1003.	0.8	8
60	Fisetin inhibits cardiac hypertrophy by suppressing oxidative stress. <i>Journal of Nutritional Biochemistry</i> , 2018, 62, 221-229.	1.9	43
61	AMPK blunts chronic heart failure by inhibiting autophagy. <i>Bioscience Reports</i> , 2018, 38, .	1.1	24
62	Prognostic Significance of Serum Cysteine-Rich Protein 61 in Patients with Acute Heart Failure. <i>Cellular Physiology and Biochemistry</i> , 2018, 48, 1177-1187.	1.1	16
63	Efficacy and tolerability of once-daily 160 mg valsartan in Chinese patients with mild to moderate hypertension. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 1109-1116.	0.8	1
64	Sestrin 1 ameliorates cardiac hypertrophy <i>via</i> autophagy activation. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 1193-1205.	1.6	40
65	A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol. <i>American Journal of Cardiology</i> , 2017, 120, 569-576.	0.7	11
66	Sestrin 2 attenuates neonatal rat cardiomyocyte hypertrophy induced by phenylephrine via inhibiting ERK1/2. <i>Molecular and Cellular Biochemistry</i> , 2017, 433, 113-123.	1.4	30
67	DJ-1 activates autophagy in the repression of cardiac hypertrophy. <i>Archives of Biochemistry and Biophysics</i> , 2017, 633, 124-132.	1.4	21
68	AMPK attenuates ventricular remodeling and dysfunction following aortic banding in mice via the Sirt3/Oxidative stress pathway. <i>European Journal of Pharmacology</i> , 2017, 814, 335-342.	1.7	18
69	Effect of Metoprolol Succinate in Patients with Stable Angina and Elevated Heart Rate Receiving Low-Dose β -Blocker Therapy. <i>International Journal of Medical Sciences</i> , 2017, 14, 477-483.	1.1	2
70	Effect of physician characteristics and knowledge on the quality of dyslipidemia management and LDL-C target goal achievement in China: Subgroup analysis of the Dyslipidemia International Study. <i>Journal of Global Health</i> , 2017, 7, 020702.	1.2	12
71	Adenosine monophosphate-activated protein kinase attenuates cardiomyocyte hypertrophy through regulation of FOXO3a/MAFbx signaling pathway. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 827-832.	0.9	5
72	Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment. <i>International Journal of Cardiology</i> , 2016, 221, 832-836.	0.8	15

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of antithrombotic regimens after coronary intervention in patients on oral anticoagulation: Traditional and Bayesian meta-analysis of clinical trials. <i>International Journal of Cardiology</i> , 2016, 205, 89-96.	0.8	25
74	Effects of Long-Term Statin Therapy in Coronary Artery Disease Patients with or without Chronic Kidney Disease. <i>Disease Markers</i> , 2015, 2015, 1-8.	0.6	5
75	AVE 3085, a novel endothelial nitric oxide synthase enhancer, attenuates cardiac remodeling in mice through the Smad signaling pathway. <i>Archives of Biochemistry and Biophysics</i> , 2015, 570, 8-13.	1.4	9
76	REDD1 attenuates cardiac hypertrophy via enhancing autophagy. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 215-220.	1.0	32
77	The critical role of Sestrin 1 in regulating the proliferation of cardiac fibroblasts. <i>Archives of Biochemistry and Biophysics</i> , 2014, 542, 1-6.	1.4	22
78	GW24-e1136...Shear stress affects the uptake of oxidised low-density lipoprotein by human vascular endothelial cells. <i>Heart</i> , 2013, 99, A49.2-A49.	1.2	0
79	Subclinical endothelial dysfunction and low-grade inflammation play roles in the development of erectile dysfunction in young man with low risk of coronary heart disease. <i>Heart</i> , 2011, 97, A242-A242.	1.2	1
80	Plasma Oxidized Low-Density Lipoprotein Is an Independent Risk Factor in Young Patients with Coronary Artery Disease. <i>Disease Markers</i> , 2011, 31, 295-301.	0.6	14